& Miller, D
One potential treatment approach involves reducing neuroinflammation through lifestyle modifications, starting with dietary changes, to address symptoms associated with brain fog
Glycine Targets According to the International Union of Basic and Clinical Pharmacology (IUPHAR), glycine has the following natural/endogenous targets: GlyRs (with 1, 2, 3, 4, and subunits), a co-agonist of ionotropic glutamate receptors (GluN1, GluN2A, GluN2B, GluN2C, and GluN2D), G protein-coupled receptor family C group 6 (GPRC6), and transporters, which move this compound across lipid membranes
Drug Pathway: No FDA New Drug Approval The FDA drug approval system is based on the NDA (New Drug Application) process